Development and optimization of a novel assay to measure neutralizing antibodies against clostridium difficile toxins

Clinical and Vaccine Immunology

Volumn 20, Issue 4, 2013, Pages 517-525

  Xie, Jinfu ^a   Zorman, Julie ^a   Indrawati, Lani ^a   Horton, Melanie ^a   Soring, Keri ^e   Antonello, Joseph M ^b   Zhang, Yuhua ^b   Secore, Susan ^a   Miezeiewski, Matthew ^e   Wang, Su ^a   Kanavage, Anthony D ^c   Skinner, Julie M ^a   Rogers, Irene ^d   Bodmer, Jean Luc ^a   Heinrichs, Jon H ^a,f  

^a Departments of Vaccine Research   (United States)

^b Non Clinical Statistics   (United States)

^c Vaccine Analytical Developmentc and Laboratory Animal Resources   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Eurofins Medinet Inc   (Germany)

^f Cambridge Discovery Park   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TOXOID A VACCINE; CLOSTRIDIUM DIFFICILE TOXOID B VACCINE; NEUTRALIZING ANTIBODY; TOXOID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY TITER; ARTICLE; AUTOMATION; CELL SEEDING DENSITY; CLOSTRIDIUM DIFFICILE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; EUKARYOTIC CELL; HAMSTER; HAPLORHINI; HUMAN; HUMAN CELL; IMMUNOASSAY; INCUBATION TIME; LINEAR SYSTEM; NONHUMAN; PRIORITY JOURNAL; SERUM; VERO CELL;

ANIMALS; ANTIBODIES, NEUTRALIZING; AUTOMATION, LABORATORY; BACTERIAL PROTEINS; BACTERIAL TOXINS; CERCOPITHECUS AETHIOPS; CLOSTRIDIUM DIFFICILE; CRICETINAE; CYTOLOGICAL TECHNIQUES; ENTEROTOXINS; MALE; MESOCRICETUS; NEUTRALIZATION TESTS; REPRESSOR PROTEINS; VERO CELLS;

EID: 84876490133     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00549-12     Document Type: Article

References (27)

1. Leffler DA, Lamont JT. 2009. Treatment of Clostridium difficileassociated disease. Gastroenterology 136:1899-1912.
2. Kelly CP, LaMont JT. 2008. Clostridium difficile-more difficult than ever. N. Engl. J. Med. 359:1932-1940.
3. O'Connor JR, Johnson S, Gerding DN. 2009. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136:1913-1924.
4. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: Mechanism of action and role in disease. Clin. Microbiol. Rev. 18:247-263.
5. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713.
6. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179.
7. Aktories K, Barbieri JT. 2005. Bacterial cytotoxins: Targeting eukaryotic switches. Nat. Rev. Microbiol. 3:397-410.
8. Jank T, Aktories K. 2008. Structure and mode of action of clostridial glucosylating toxins: The ABCD model. Trends Microbiol. 16:222-229.
9. Barth H, Pfeifer G, Hofmann F, Maier E, Benz R, Aktories K. 2001. Low pH-induced formation of ion channels by Clostridium difficile toxin B in target cells. J. Biol. Chem. 276:10670-10676.
10. Giesemann T, Egerer M, Jank T, Aktories K. 2008. Processing of Clostridium difficile toxins. J. Med. Microbiol. 57:690-696.
11. Rupnik M, Pabst S, Rupnik M, von Eichel-Streiber C, Urlaub H, Soling HD. 2005. Characterization of the cleavage site and function of resulting cleavage fragments after limited proteolysis of Clostridium difficile toxin B (TcdB) by host cells. Microbiology 151:199-208.
12. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. 2012. Clostridium difficile: Development of a novel candidate vaccine. Vaccine 30:4307-4309.
13. Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC. 2012. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 30:4249-4258.
14. Kotloff KL, Wasserman SS, Losonsky GA, Thomas W, Jr, Nichols R, Edelman R, Bridwell M, Monath TP. 2001. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect. Immun. 69:988-995.
15. Torres JF, Lyerly DM, Hill JE, Monath TP. 1995. Evaluation of formalininactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect. Immun. 63:4619-4627.
16. Marozsan AJ, Ma D, Nagashima KA, Kennedy BJ, Kenneth Kang Y, Arrigale RR, Donovan GP, Magargal WW, Maddon PJ, Olson WC. 25 June 2012. Protection against Clostridium difficile infection with broadly neutralizing anti-toxin monoclonal antibodies. J. Infect. Dis. doi:10.1093 /infdis/jis416.
17. Torres J, Camorlinga-Ponce M, Munoz O. 1992. Sensitivity in culture of epithelial cells from rhesus monkey kidney and human colon carcinoma to toxins A and B from Clostridium difficile. Toxicon 30:419-426.
18. Aboudola S, Kyne KKL, Warny M, Kelly EC, Sougioultzis S, Giannasca PJ, Monath TP, Kelly CP. 2003. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin. Infect. Immun. 71:1608-1610.
19. Kyne L, Qamar WMA, Kelly CP. 2000. Asymptomatic carriage of Clos-tridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397.
20. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D. 2010. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:965-969.
21. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, Kelly CP. 2005. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128:764-770.
22. Clark GF, Krivan HC, Wilkins TD, Smith DF. 1987. Toxin A from Clostridium difficilebindsto rabbit erythrocyte glycolipidswithterminalGalalpha1-3Galbeta 1-4GlcNAc sequences. Arch. Biochem. Biophys. 257:217-229.
23. Krivan HC, Clark GF, Smith DF, Wilkins TD. 1986. Cell surface binding site for Clostridium difficile enterotoxin: Evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect. Immun. 53:573-581.
24. Tucker KD, Wilkins TD. 1991. Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect. Immun. 59: 73-78.
25. Pothoulakis C, LaMont JT, Eglow R, Gao N, Rubins JB, Theoharides TC, Dickey BF. 1991. Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. J. Clin. Invest. 88:119-125.
26. Ghose C, Kalsy A, Sheikh A, Rollenhagen J, John M, Young J, Rollins SM, Qadri F, Calderwood SB, Kelly CP, Ryan ET. 2007. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect. Immun. 75:2826-2832.
27. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD, Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74:6339-6347.